REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM
Clinical trials for REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control OngoingThis study tests a drug called ulixertinib in children and teens with advanced solid tumors, lymphoma, or histiocytic disorders that have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the growth of these cancers. About 20 partici…
Matched conditions: REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:10 UTC
-
Engineered immune cells injected into the brain take on childhood cancers
Disease control OngoingThis early-stage study tests a new treatment for children and young adults with certain hard-to-treat brain tumors, including DIPG and DMG. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack tumor cells, then delivered directly …
Matched conditions: REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated May 26, 2026 10:05 UTC
-
New hope for kids with rare cancers: drug blocks tumor growth
Disease control OngoingThis study tests a daily pill called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. The drug works by blocking signals that help tumors grow and form blood vessel…
Matched conditions: REFRACTORY PRIMARY MALIGNANT CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:19 UTC